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significantly higher (p < 0.001) when advising patients on 
vitamin K antagonists (VKAs) versus non-vitamin K antago-
nists (NOACs). In general, hospital pharmacists displayed 
higher confidence levels compared to community pharma-
cists when advising patients on anticoagulation (p < 0.001). 
Two distinct patterns of confidence levels emerged relating 
to basic and advanced pharmaceutical care. Confidence lev-
els when providing advanced pharmaceutical care were sig-
nificantly higher for Oceania and lower for South America 
(p < 0.005). Conclusions Pharmacists felt more confident 
in supporting patients receiving VKAs compared to the 
more recently introduced NOACs. With the increasing use 
of NOACs and the risks pertaining to anticoagulation ther-
apy, it is essential to invest in education for pharmacists to 
address their knowledge gaps enabling them to confidently 
support patients receiving oral anticoagulants.
Abstract Background Guidelines on the management of 
orally anticoagulated patients are continuously evolving, 
leading to an increased need for pharmacists to be fully inte-
grated in care provision. Objective To identify self-reported 
gaps in confidence among practicing pharmacists in the area 
of anticoagulation. Setting Pharmacists in different work set-
tings in different countries. Method Cross-sectional interna-
tional survey from October 2015 till November 2016 among 
pharmacists working in different settings to assess their level 
of confidence when delivering anticoagulants as well as to 
identify possible educational needs regarding this medica-
tion class. Validation of the survey was ensured. Results 
Responses from 4212 pharmacists originating from 18 coun-
tries were obtained. Pharmacists’ level of confidence was 
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Impact of findings on practice
• Education of pharmacists in anticoagulation is essential 
for improved pharmaceutical patient care
• Pharmacists perceive a greater need for education on 
more recently marketed anticoagulants
• Pharmacists identify e-learning as the preferred method 
of educational content delivery
Introduction
Venous thromboembolism (VTE) and atrial fibrillation 
(AF) are two health conditions that require complex anti-
coagulation therapy for management and for prevention of 
life-threatening thromboembolic events. It is estimated that 
10 million new cases of VTE are diagnosed annually result-
ing in over 544,000 deaths per year in Europe and 300,000 
deaths per year in the US [1–3]. As 60% of VTE cases occur 
after hospitalization, it is a leading preventable cause of 
hospital-related death [1]. Globally, there are 33.5 million 
patients afflicted with AF [4]. It has been reported that as 
many as 10–27% of patients with AF remain undiagnosed 
[5]. AF can lead to ischemic stroke, and patients with AF are 
at a five-fold increased risk of stroke compared to the gen-
eral population [6]. Depending on an individual’s  CHADS2 
score, the estimated risk of stroke ranges from 1.9 to 18.2% 
if a patient with AF does not receive anticoagulation [7]. In 
the US, 1 in 5 of the 700,000 strokes which occur annually 
are attributed to AF, and this proportion increases to 1 in 3 
in those aged over 80 years [8]. Ultimately, patients with AF 
have a two-fold increased risk of mortality compared to the 
general population [6].
Oral anticoagulants are the standard modality for the 
treatment of these conditions. Compared to placebo, there 
is an 83% decrease in the recurrence of VTE with warfarin 
or non-vitamin K oral anticoagulant (NOAC) therapy [9]. 
Likewise, warfarin reduces the risk of ischemic stroke by 
60% in patients with AF [10]. Comparatively, the NOACs 
have been shown to be either non-inferior or superior when 
compared to warfarin for stroke prophylaxis in AF [11–14].
Although warfarin was the most widely used OAC glob-
ally since its approval in 1954, the use of NOACs has 
steadily increased since the availability of dabigatran in 
2008. In 2014, NOACs accounted for 15.5% of the global 
anticoagulant market whereas warfarin use had declined 
to 72% [15]. Furthermore, studies have estimated a three-
fold increase in NOAC use between 2013 and 2014 in the 
United States (US) for AF [16]. This increase in use is 
likely attributed to the demonstrated safety, efficacy, and 
convenience of the newer agents, and the lack of interna-
tional normalized ratio (INR) monitoring or individualized 
dose adjustments [11–14]. Nonetheless, patients are less 
likely to receive frequent follow-up as there is no standard-
ized routine monitoring performed to assess the anticoagu-
lation effects of the NOACs [17, 18]. While INR may serve 
as an indicator of patient adherence with warfarin, patient 
self-reported intake is the predominant adherence assess-
ment used with NOACs [19]. A recent dabigatran analysis 
revealed that a 10% decrease in adherence resulted in a 
13% increased stroke risk secondary to AF [20]. As such, 
patient monitoring, education, and medication adherence 
are of critical importance with these novel agents, given 
the difference in methods for assessing it as well as the 
consequences of non-adherence due to the NOACs’ shorter 
half-lives.
The scope of pharmacy practice continues to evolve 
globally, and pharmacists are uniquely positioned to play 
a broader role in anticoagulation medication management. 
Several studies have documented the positive impact from 
pharmacists in monitoring and managing warfarin in the 
community setting. These benefits include an increased 
percentage of INR measurements within therapeutic range, 
increased patient understanding of their medication, and 
reduced-rates of anticoagulation-related emergency room 
visits and hospitalizations [21–23]. Given that self-reported 
adherence rates with NOACs are as low as 57% [24], phar-
macists may be able to have a similar impact on patients 
receiving NOAC therapy.
The International Pharmacists for Anticoagulation Care 
Taskforce (iPACT) is an expert group committed to further 
enhance the key role pharmacists play in anticoagulation 
management. Whilst pharmacists are well suited to monitor 
patients receiving oral anticoagulation, to our knowledge, 
an assessment of their knowledge in providing consulta-
tions has not been formally undertaken. Historically, needs 
assessment surveys have been successfully used to identify 
the self-perceived confidence of pharmacists in emerging 
therapeutic fields and to identify professional needs prior to 
developing continuing professional education and develop-
ment programs [25, 26].
Aim of the study
The main study purpose was to identify self-reported gaps in 
knowledge and confidence among pharmacists in the area of 
anticoagulation and to explore preferred educational meth-
ods to close these gaps. An additional objective was to iden-
tify any difference in confidence levels between countries.
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Ethics approval
This study was centrally approved by the Comissão de Ética 
Egas Moniz in Portugal (Process no. 489). In all countries, 
pharmacists were free to decline participation. The prin-
ciples of ethical research practices were followed, such as 
confidentiality, freedom to participate or withdraw at any 
stage, and anonymity.
Methods
Design and procedure
This study was a cross-sectional international survey (avail-
able as electronic supplementary material) among pharma-
cists working in different settings to assess their level of 
confidence when delivering anticoagulants as well as to 
identify possible educational needs regarding this medica-
tion class. The questionnaire was originally developed and 
validated in English, following literature review, consulta-
tion with external experts and input from iPACT members 
experienced in survey development. The Decipher software 
(version M35; Quest Mindshare, Toronto, Canada) was used 
for developing the web-based survey; and data extraction 
was programmed on WinCross 14.0. The questionnaire con-
sisted of three parts. The first part (including 6 items) col-
lected participants’ demographic information such as years 
of work experience, level of education and area of practice. 
The second part (including 13 items) explored pharmacists’ 
confidence levels when advising patients on various aspects 
of anticoagulation medication, and was ranked on a 4 point 
Likert scale, ranging from “very confident” to “not confi-
dent at all”. The second part of the survey also asked about 
information sources sought to support patient counselling. 
The last part (including 6 items) gauged the perceived edu-
cational needs of the pharmacists and asked about the pre-
ferred format and tools to deliver this education. The survey 
was translated into 19 different languages and distributed 
in 22 countries after being piloted. Piloting was performed 
by administration to 10 pharmacists per country and to 
assess the burden, applicability, and acceptability among 
respondents. Subsequently, the first countries where data 
collection was undertaken (France and Canada), were used 
to validate the survey, which comprised testing psychomet-
ric properties in a sample of respondents. The process was 
then replicated in all participating countries. The survey was 
distributed electronically using each iPACT country coordi-
nator’s network. The most common method involved using 
the national and/or regional professional pharmacy associa-
tions for dissemination. Since countries joined the project at 
different times, the survey was allowed to run from October 
2015 until November 2016. In all countries, the national 
coordinator was free to decide on the length of data col-
lection, which depended mainly on the partner associations 
involved in disseminating the survey and the time to reach 
the minimum number of 50 respondents per country. The 
minimum period to achieve this was 1 month and the maxi-
mum 6 months. In all countries, mail alerts were used as a 
reminder technique to increase the response rate.
Statistical analysis
The survey’s construct validity was examined using fac-
tor analysis. Internal consistency and homogeneity were 
examined by calculating Cronbach’s alpha. Categorical 
data was summarized as frequencies and percentages. 
Comparison between groups was performed using the Chi 
square test while comparison of continuous variables was 
performed using independent sample t test or ANOVA. 
Depending on the number of groups under comparison, 
Bonferroni post hoc tests were utilized as required. Linear 
regression was performed to assess the effects of potential 
predictors on pharmacists’ confidence levels (dependent 
variable) when advising patients on anticoagulation medi-
cation. Predictors tested (independent variables) included 
age, years of experience, educational level, area of practice 
and country of origin. Statistical analyses were executed 
with a 0.05 significance level using IBM SPSS Statistics 
version 23 (IBM Corp., Armonk, NY, USA).
Results
Characterisation of respondents
A total of 4255 responses from 21 countries were col-
lected. Countries with no responses (Peru) or with a low 
response rate (USA, Slovenia and Chile) were subse-
quently excluded. As such, 18 countries with a total of 
4212 responses were retained in the final analysis (Fig. 1). 
The final list of the countries included were representa-
tive of Europe (66.7%), North and South America (5.6 
and 11.1%, respectively), Oceania (11.1%), and the Gulf 
Council Countries (5.6%).
The majority of respondents were female pharmacists 
(n = 3045; 72.3%), mostly middle aged between 30 and 
50 years. Experience in pharmacy varied widely, unlike 
formal education where only a minority held a PhD. 67.7% 
(n = 2852) of respondents worked in a community phar-
macy, while 27.5% (n = 1157) worked in a hospital. Other 
areas of employment, including academia, the pharmaceuti-
cal industry, and independent consultancy firms, represented 
a much lower proportion of the sample population.
 Int J Clin Pharm
1 3
Confidence levels of pharmacists
Pharmacists’ level of confidence was significantly higher 
when advising patients on vitamin K antagonists (VKAs) 
versus NOACs (p < 0.001) (Fig. 2).
Distinct patterns in confidence level were observed 
depending on the surveyed items (Fig. 3). There were no 
differences in the confidence levels that could be explained 
by the age of pharmacists, their experience of pharmacy 
practice or additional formal education (p > 0.05) (results 
not shown). In general, hospital pharmacists displayed 
higher confidence levels compared to community pharma-
cists when advising patients on anticoagulation (p < 0.001). 
However, country specific differences in confidence levels 
associated with area of practice were observed; for instance 
in Belgium, community pharmacists performed similarly to 
hospital pharmacists.
The underlying themes included in the questionnaire 
could be clustered into two main categories. The first group 
focused on delivering drug and disease-related information 
such as drug indications or expected benefits of treatment. 
In some countries, this practice is a compulsory part of basic 
pharmaceutical care. The second category included deliver-
ing more advanced pharmaceutical care and requiring the 
pharmacist to manage more complex issues such as the iden-
tification and treatment of bleeds. This categorization was 
confirmed by the rotated factor plotting, clearly visualizing 
that the individual items load into the respective components 
described (Fig. 4).
The two components shown in Fig. 4, basic pharmaceuti-
cal care and advanced pharmaceutical care, displayed high 
internal consistency in the overall sample (α = 0.851 and 
α = 0.877, respectively), with insignificant variations at the 
country level (ranging from 0.757 to 0.878 for component 1 
and from 0.772 to 0.924 for component 2).
Analysis of confidence levels by continent of origin iden-
tified differences between the groups for the two compo-
nents (p < 0.001). Post-hoc analysis highlighted that with 
regard to confidence levels when providing patients with 
basic pharmaceutical care (component 1), only South Amer-
ican countries performed significantly lower than all others 
(p < 0.001). On the other hand, two extremes in confidence 
levels were detected when providing patients with advanced 
pharmaceutical care (component 2). South American coun-
tries performed significantly lower and Oceania performed 
significantly better (p < 0.005) in this regard compared to 
all others (Fig. 5).
Linear regression was used to analyse predictors of phar-
macists’ confidence levels. Two independent models were 
considered, where component 1 and component 2 were the 
dependent variables. Whilst both models were found to pre-
dict very little of the variability  (R2 = 0.196 and  R2 = 0.233, 
respectively), the same variables were found to influence 
confidence levels, suggesting that gender, length of expe-
rience, post-graduate education, and area of practice may 
indeed partly explain self-confidence. On the other hand, 
continent of origin was identified as an additional predictor 
but only for component 2 (Table 1).
Fig. 1  Distribution of respondents to the iPACT survey by country of origin
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Preferred sources of information for pharmacists 
and educational needs
When dispensing anticoagulants, pharmacists chose spe-
cialized pharmacy software as their preferred source of 
information (n = 2350; 55.8%), followed by the internet 
(n = 2186; 51.9%). Less than half of the respondents used 
reference books (n = 1790; 42.5%) or published journal 
articles (n = 1255; 29.8%).
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Fig. 2  Distribution of pharmacists’ confidence by pharmacotherapeutic group
Fig. 3  Distribution of pharma-
cists’ confidence by counselling 
item
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The majority of respondents (n = 3871; 91.9%) reported 
that they would like to receive additional education to 
improve their confidence level. The preferred areas for fur-
ther education followed an inverse trend compared to the 
expressed confidence levels. The most desired item in this 
regard was interactions (n = 2956; 70.2%), followed by man-
agement of bleeding (n = 2871; 68.2%), and management 
of switching (n = 2780; 66.0%). Management of bleeding 
was among the top areas receiving educational requests, 
while learning about the coagulation pathway was the least 
requested topic (n = 1322; 31.4%).
The most popular formats of education were personal-
ized e-learning (n = 2490; 59.1%), interactive websites 
(n = 1760; 41.8%) and symposia (n = 1757; 41.7%). The 
least preferred formats identified were education from 
peers (n = 493; 11.7%), webinars (n = 970; 23.0%) and 
workshops (n = 1473; 35.0%). While these results reflect 
the overall trend, there were country-specific behaviours, 
where for example education from peers was more pop-
ular among Dutch pharmacists and webinars amongst 
Croatians pharmacists.
In addition to education, pharmacists expressed the 
need to have a list of frequently asked questions to sup-
port them while counselling patients (n = 4043; 96.0%). 
A quick reference guide was proposed as a solution, either 
embedded in the pharmacy software (2754; 65.4%), as a 
link to a website (n = 2200; 52.2%) or as a specific app 
(n = 1797; 42.7%). Non-technological solutions were less 
favoured, e.g. the availability of a pocket guide.
Fig. 4  Component plot in 
rotated space
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Discussion
To the best of our knowledge, this is the first global study 
that reports data from pharmacists on perceived gaps in 
confidence and training needs in the area of anticoagula-
tion therapy. The diverse, transcontinental sample provides 
a valuable snapshot of the status of pharmacists with respect 
to their preparedness to provide counselling and education 
related to these potentially risky treatment modalities.
Non-vitamin K oral anticoagulants have been intro-
duced into the market relatively recently as an alternative 
to warfarin, and our results showed a higher level of confi-
dence among pharmacists advising patients on VKAs than 
on NOACs. This reflects the long experience with VKAs, 
which have been the mainstay of treatment globally for a 
much longer period. However, the complexity of therapies 
associated with VTE and AF requires an advanced level of 
practice, regardless of the anticoagulant used. Warfarin is 
consistently reported within the top 3 medications associ-
ated with an adverse reaction leading to a hospital admis-
sion [27]. Guidelines recommend that healthcare provid-
ers who are managing oral anticoagulation therapy should 
incorporate, in a coordinated manner, patient education, 
patient tracking and follow-up and good patient communi-
cation regarding the results and dosing decisions [28, 29]. 
For patients receiving VKA anticoagulation therapy, careful 
INR testing is key to ensuring treatment success, preventing 
thromboembolic events, and managing bleeding risks. Such 
an advanced level of practice is typically seen in countries 
known to have well-developed pharmacy practice standards 
and regulations that support those standards. The results 
with respect to pharmacist confidence levels with anticoagu-
lation therapies mirrored this relationship. Respondents from 
Ireland, the UK, the Netherlands, Australia, Canada, and 
New Zealand expressed higher levels of confidence in deal-
ing with VKAs and NOACs than respondents from the other 
countries. Respondents from South America were persis-
tently less confident. Experience with NOACs and their use 
in routine practice differs between countries; and this may 
be influenced by health economics, pricing, and coverage by 
different health systems [28]. Higher gross domestic product 
(GDP) countries, for example, do tend to have advanced 
pharmacy practice in contrast with lower GDP nations [30]. 
This most likely explains the reason for the higher confi-
dence illustrated in our results. Site of practice also has an 
association with the level of perceived confidence in deal-
ing with anticoagulation management. In general, hospital 
pharmacists expressed higher confidence than pharmacists 
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America 
South 
America 
Asia* 
*(Gulf Council 
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Europe Oceania North 
America 
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Fig. 5  Comparison of confidence levels by continent of practice of pharmacists
Table 1  Results from linear regression using components 1 and 2 on 
“confidence when advising patients on anticoagulation care” as the 
dependent variable (n = 4212)
Adjusted β 95% CI p-value
Factor 1: Basic pharmaceutical care
Constant 18.318;19.991 < 0.001
Gender − 0.159 − 1.399; − 0.953 < 0.001
Experience of pharmacy 0.096 0.138; 0.265 < 0.001
Additional education 0.041 0.023; 0.162 0.009
Area of practice − 0.035 − 0.357; − 0.024 0.025
Factor 2: Advanced pharmaceutical care
Constant 13.744; 15.618 < 0.001
Gender − 0.157 − 1.560; − 1.060 < 0.001
Experience of pharmacy 0.084 0.128; 0.271 < 0.001
Additional education 0.083 0.271; 0.294 < 0.001
Area of practice − 0.074 − 0.643; − 0.270 < 0.001
Continent 0.090 0.756; 1.511 < 0.001
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in other localities. This could be attributed to several fac-
tors. For example, the job demands in a hospital setting, the 
interprofessional environment in hospital practice, and the 
opportunity for professional development in many hospitals 
could explain this result. In contrast, community pharmacy 
in ‘developing’ countries is still dominated by the more tra-
ditional dispensing practice.
Over 90% of the participants expressed desire for some 
sort of continuing education on different aspects of anti-
coagulation management. Assessing training needs was an 
important objective in this study. While this was an oppor-
tunity for reflection from the perspective of the pharmacist, 
it helps in the development of relevant educational programs 
tailored to the perceived needs. The results of this study 
have also provided us with an insight on what informa-
tion is desired, and in what format this information should 
be provided. Methods for learning spanned a wide range 
of options, with e-learning and interactive websites being 
the most popular. All this information should prove invalu-
able in developing continuous education materials to close 
the knowledge gaps identified by this study. Other studies 
using similar (web-based survey) or comparable techniques 
(interview, questionnaire) have also identified pharmacists’ 
knowledge gaps and education needs in domains such as 
transplantation, travel health, weight loss and oral health 
[31–34].
This study has some limitations, including the inability 
to include a larger sample in some relevant countries repre-
sented by iPACT members, like the USA or Chile, leading 
us to exclude them in the final analysis. Nonetheless, data 
collection is ongoing in these countries and may be used in 
the future to shape pharmacists’ education. The inability to 
represent African countries and include only Gulf Council 
countries (Kuwait, Qatar, Saudi Arabia and the United Arab 
Emirates) as representatives of the Asian continent limits 
comparisons. However, the similarities in pharmacy prac-
tice, demographics and education of Gulf Council countries 
allowed for a valid grouping of these individual countries 
[35]. Within participating countries, selection bias may have 
occurred by using an internet survey. However, in Portugal 
data was compared against national data of pharmacists’ 
demographics, and this showed only minor discrepancies 
[36]. The simplified translation process utilized may have led 
to some inadequate terminology use, but the high consist-
ency evidenced led us to discard this possibility.
Conclusion
Pharmacists reported higher confidence in supporting 
patients receiving VKAs compared to the more recently 
introduced NOACs. Consistently, pharmacists had greatest 
confidence in explaining the indication and the benefits of 
anticoagulation and lowest confidence in managing bleeding 
and switching amongst oral anticoagulants. With the increas-
ing use of NOACs and the known risks pertaining to anti-
coagulation therapy, it is essential to invest in education for 
pharmacists to address their knowledge gaps enabling them 
to confidently support patients receiving oral anticoagulants.
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